Q-linea AB (publ) announced that Stuart Gander succeeds Jonas Jarvius as CEO. Stuart Gander brings extensive experience from leading positions in the global healthcare industry, with a focus on diagnostics and medical technologies. Through his management consulting background, he has supported companies on a range of operational challenges with a focus on driving sustainable change and growth, based on building strong and motivated teams. Stuart Gander is a Canadian citizen, has previously been working 15 years in Sweden, is currently living in the USA but will relocate to Sweden within the next 18 months.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.365 SEK | +5.58% | -8.86% | -36.08% |
Apr. 26 | Q-Linea AB Receives FDA 510(k) Clearance for the ASTar® System | CI |
Mar. 13 | Q-linea AB Presents Strong ASTar Results At AMCLI | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-36.08% | 24.22M | |
-16.27% | 18.77B | |
-41.10% | 2.9B | |
+24.02% | 1.97B | |
+8.62% | 1.82B | |
+26.33% | 1.25B | |
-7.74% | 1.06B | |
-18.61% | 936M | |
-1.18% | 770M | |
-23.76% | 639M |
- Stock Market
- Equities
- QLINEA Stock
- News Q-linea AB
- Q-linea AB Announces CEO Changes